Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vistusertib in Relapsed SCLC with RICTOR Amplification
NCT03106155Phase 2Terminated
- Sponsor
- Samsung Medical Center
- Start
- Aug 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vistusertib in small cell lung cancer (SCLC), sponsored by Samsung Medical Center. Started Aug 2017; status: terminated.
02
Drugs
vistusertib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03106155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03106155.